Analyst Ratings for Bio-Rad Laboratories Inc. Cl A (BIO)

Updated: 2017-07-29

Shares of Bio-Rad Laboratories Inc. Cl A (NYSE:BIO) have received a consensus rating of Buy from Wall Street analysts. About 30 days ago, BIO was issued an average rating of Overweight.

Of the 4 analysts covering the stock, 3 gave it a buy rating, 1 gave an overweight rating, 0 issued a hold rating, 0 gave an underweight rating, and 0 issued a sell rating. Compared to three months ago, there has been an increase of 2 in the number of analysts with a positive outlook on the stock. Meanwhile, the number of analysts pessimistic about the company has increased by 0.

Several price targets were given for BIO by the analysts covering the stock. The maximum price target given was 275, which equates to a potential upside of 16.35 percent. The most pessimistic price target was 245, implying a possible loss of 3.66 percent. Note that investment analysts can be biased in their reporting on companies's ratings and price targets.

Analysts have revised their earnings estimates upwards for this quarter, by about 14.42 percent on average, compared to last month. This can be compared with the average change in earnings estimates over the past 3 months, which is -16.21 percent. Over the past 30 days, FY earnings estimates have also changed upwards by 3.5 percent. If we look at the last 90 days instead, we find a net average change of 6.68 percent in FY estimates.

People are often interested in whether analysts were united in the direction of their revisions. Over the past month, 1 analysts increased their quarterly estimates, while 0 analysts revised their estimates downwards. Over the same time period, 1 analysts revised their FY earnings estimates upwards, compared to 0 analysts that revised their FY estimates downwards.

The growth rate of BIO's earnings is estimated by analysts to be 215.57 percent. Another measure frequently examined by investors is the PEG ratio. Smaller PEG ratios are desirable, as that can indicate whether the high price level of a stock is warranted by high growth. PEG ratios below 1 are often considered desirable, but many choose to perform ratio comparisons with other companies in the industry. The PEG ratio of BIO is 1.17.

BIO has a 52-week high of 239.91 and a 52-week low of 143.39. The current market price is above the trailing year's low by 64.84 percent, and below the high by 1.48 percent. BIO has a price/earnings ratio of 251.45. Investors typically compare the P/E ratio to a company's peers in the industry. The BIO value stock report compares BIO to some of its peers using value stock charts. The stock has a market capitalization of $7.03 billion. BIO is estimated to release their earnings results for the quarter on 0000-00-00, days from today.